Teva Pharmaceutical Industries Stock Forecast, Price & News

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TEVA shares have decreased by 4.1% and is now trading at $8.64.
View which stocks have been most impacted by COVID-19.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 9 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its earnings results on Wednesday, August, 5th. The company reported $0.55 EPS for the quarter, topping the Zacks' consensus estimate of $0.53 by $0.02. The company earned $3.87 billion during the quarter, compared to analysts' expectations of $3.94 billion. Teva Pharmaceutical Industries had a return on equity of 17.88% and a net margin of 0.03%. The business's quarterly revenue was down 7.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.60 earnings per share.
View Teva Pharmaceutical Industries' earnings history.

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, August, 5th. The company provided earnings per share (EPS) guidance of $2.30 to $2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.49. The company issued revenue guidance of $16.6 billion to $17 billion, compared to the consensus revenue estimate of $16.83 billion.

18 analysts have issued 12-month price targets for Teva Pharmaceutical Industries' stock. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $12.36 in the next year. This suggests a possible upside of 43.0% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries.

News coverage about TEVA stock has trended extremely negative on Thursday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days.
View the latest news about Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Beigene (BGNE), Genmab A/S (GMAB), Shiseido (SSDOY), UCB (UCBJF), Genmab A/S (GNMSF), Merck KGaA (MKGAF), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN) and Catalent (CTLT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Intel (INTC), Bank of America (BAC), Gilead Sciences (GILD), Cisco Systems (CSCO) and Johnson & Johnson (JNJ).

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries' stock is owned by a variety of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (1.64%), Phoenix Holdings Ltd. (1.07%), FMR LLC (0.75%), Harel Insurance Investments & Financial Services Ltd. (0.70%), Swiss National Bank (0.40%) and Sumitomo Mitsui Trust Holdings Inc. (0.38%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Two Sigma Advisers LP, Psagot Investment House Ltd., Alberta Investment Management Corp, State of Wisconsin Investment Board, Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, and Cambridge Investment Research Advisors Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Michael James Mcclellan, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries.

TEVA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Menora Mivtachim Holdings LTD., Teacher Retirement System of Texas, Harel Insurance Investments & Financial Services Ltd., Nuveen Asset Management LLC, ArrowMark Colorado Holdings LLC, and Schonfeld Strategic Advisors LLC.
View insider buying and selling activity for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $8.64.

Teva Pharmaceutical Industries has a market capitalization of $9.44 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]